VERELAN Drug Patent Profile

✉ Email this page to a colleague

When do Verelan patents expire, and when can generic versions of Verelan launch?

Verelan is a drug marketed by Azurity and is included in two NDAs.

The generic ingredient in VERELAN is verapamil hydrochloride. There are seventeen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Verelan

A generic version of VERELAN was approved as verapamil hydrochloride by EXELA PHARMA on March 30^th, 1984.

Subscribe

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for VERELAN?
What are the global sales for VERELAN?
What is Average Wholesale Price for VERELAN?

Summary for VERELAN

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	78
Clinical Trials:	12
Patent Applications:	4,352
Drug Prices:	Drug price information for VERELAN
What excipients (inactive ingredients) are in VERELAN?	VERELAN excipients list
DailyMed Link:	VERELAN at DailyMed

Drug patent expirations by year for VERELAN

Recent Clinical Trials for VERELAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assiut University	Early Phase 1
Theracos	Phase 1
City of Hope Medical Center	Phase 1

See all VERELAN clinical trials

Pharmacology for VERELAN

Drug Class	Calcium Channel Blocker
Mechanism of Action	Calcium Channel Antagonists Cytochrome P450 3A Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for VERELAN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-001	May 29, 1990	AB	RX	Yes	No	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Azurity	VERELAN PM	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020943-003	Nov 25, 1998		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-004	May 10, 1996		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for VERELAN

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-001	May 29, 1990	4,863,742	⤷ Subscribe
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-004	May 10, 1996	4,863,742	⤷ Subscribe
Azurity	VERELAN	verapamil hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019614-003	Jan 9, 1992	4,863,742	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for VERELAN

See the table below for patents covering VERELAN around the world.

Subscribe to access the full database, or Subscribe
Country	Patent Number	Title	Estimated Expiration
Japan	S635021	ABSORPTION CONTROLLED DRUG COMPOSITION	⤷ Subscribe
Japan	2637981		⤷ Subscribe
Greece	3003978		⤷ Subscribe
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for VERELAN

Recent Clinical Trials for VERELAN

Pharmacology for VERELAN

Make Better Decisions: Try a trial or see plans & pricing